EUVIMEDEUVIMED entdecken
Open Access

The clinical antiprotozoal drug halofuginone promotes weight loss by elevating GDF15 and FGF21

Suowen Xu iD, Zhenghong Liu iD, Tian Tian iD, Wenqi Zhao iD, Zhihua Wang iD, Monan Liu, Mengyun Xu iD, Fanshun Zhang, Zhidan Zhang iD, Meijie Chen, Yanjun Yin iD, Meiming Su iD und 11 weitere

Science Advances · 2025

DOI: 10.1126/sciadv.adt3142 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Suowen Xu und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sc…. Hauptthemen laut MEDLINE: Fibroblast Growth Factors, Quinazolinones, Growth Differentiation Factor 15, Piperidines. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obesity is a debilitating global pandemic with a huge cost on health care due to it being a major underlying risk factor for several diseases. Therefore, there is an unmet medical need for pharmacological interventions to curb obesity. Here, we report that halofuginone, a Food and Drug Administration–approved anti-scleroderma and antiprotozoal drug, is a promising anti-obesity agent in preclinical mouse and pig models. Halofuginone suppressed food intake, increased energy expenditure, and resulted in weight loss in diet-induced obese mice while also alleviating insulin resistance and hepatic steatosis. Using molecular and pharmacological tools with transcriptomics, we identified that halofuginone increases fibroblast growth factor 21 (FGF21) and growth differentiation factor 15 (GDF15) levels via activating integrated stress response. Using Gdf15 and Fgf21 knockout mice, we show that both hormones are necessary to elicit anti-obesity changes. Together, our study reports the beneficial metabolic effects of halofuginone and underscores its utility in treating obesity and its associated metabolic complications, which merits clinical assessment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fibroblast Growth FactorsQuinazolinonesGrowth Differentiation Factor 15PiperidinesWeight LossObesityAntiprotozoal AgentsAnimalsMiceMice, KnockoutMaleDisease Models, AnimalEnergy MetabolismInsulin ResistanceSwineMice, Inbred C57BLHumans

Substanzen

halofuginoneFibroblast Growth FactorsQuinazolinonesfibroblast growth factor 21Growth Differentiation Factor 15PiperidinesAntiprotozoal AgentsGdf15 protein, mouse

Autor:innen und Institutionen

  • Department of Endocrinology, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, He…
  • Anhui Provincial Key Laboratory of Metabolic Health and Panvascular Diseases, Hefei 230001, China.
  • Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim 61231, Germany.
  • Institute of Endocrine and Metabolic Diseases, University of Science and Technology of China, Hefei 230001, China.
  • The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China.
  • Laboratory of Precision and Intelligent Chemistry, Department of Polymer Science and Engineering, University of Science and Technology of China, Hefei 230026, China.

ORCID-Profile: Suowen Xu, Zhenghong Liu, Tian Tian, Wenqi Zhao, Zhihua Wang, Mengyun Xu, Zhidan Zhang, Yanjun Yin, Meiming Su, Wenxiang Fang, Wenhao Pan, Shiyong Liu, Min-Dian Li, Peter J Little, Danielle Kamato, Dongdong Wang, Stefan Offermanns, John R Speakman, Jianping Weng

Zitieren

APA

Xu, S., Liu, Z., Tian, T., Zhao, W., Wang, Z., Liu, M., Xu, M., Zhang, F., Zhang, Z., Chen, M., Yin, Y., Su, M., Fang, W., Pan, W., Liu, S., Li, M. D., Little, P. J., Kamato, D., Zhang, S., …, & Weng, J. (2025). The clinical antiprotozoal drug halofuginone promotes weight loss by elevating GDF15 and FGF21. Science Advances. https://doi.org/10.1126/sciadv.adt3142

Vancouver

Xu S, Liu Z, Tian T, Zhao W, Wang Z, Liu M, et al. The clinical antiprotozoal drug halofuginone promotes weight loss by elevating GDF15 and FGF21. Science Advances. 2025. doi:10.1126/sciadv.adt3142

BibTeX
@article{Xu2025,
  author = {Xu, Suowen and Liu, Zhenghong and Tian, Tian and Zhao, Wenqi and Wang, Zhihua and Liu, Monan and Xu, Mengyun and Zhang, Fanshun and Zhang, Zhidan and Chen, Meijie and Yin, Yanjun and Su, Meiming and Fang, Wenxiang and Pan, Wenhao and Liu, Shiyong and Li, Min-Dian and Little, Peter J and Kamato, Danielle and Zhang, Songyang and Wang, Dongdong and Offermanns, Stefan and Speakman, John R and Weng, Jianping},
  title = {The clinical antiprotozoal drug halofuginone promotes weight loss by elevating GDF15 and FGF21},
  journal = {Science Advances},
  year = {2025},
  doi = {10.1126/sciadv.adt3142}
}
Kostenlos starten →